The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Approval and access to COVID19 vaccines for people living with SMA. What is happening in the European Union and the UK’s initial experience, where the first person was immunised this week.

    Access to COVID19 vaccines will differ throughout Europe as approval is granted. The United Kingdom (UK) is the first to have approved BNT162b2, a COVID19 vaccine developed by Pfizer/BioNTech. Here, we describe how our member, SMA UK, is working to ensure access to people living with SMA and other muscle-wasting conditions. We also highlight a […]


  2. Welcoming 3 countries to SMA Europe

    We are delighted to have welcomed three new organisations into our fold: MDA Hellas (Greece) MDA Hellas is a muscular disease association founded in 2000, which focuses on improving the lives of individuals with neuromuscular disorders: not only on forging a lasting working relationship with government agencies and on enlisting the help of private institutions […]


  3. Nicole Gusset appointed President of SMA Europe with immediate effect

    SMA Europe is delighted to announce that Nicole Gusset has been appointed as President. This appointment is effective immediately and follows Mencía de Lemus’ decision to step down as president of SMA Europe. We are fortunate to have someone of Nicole Gusset’s calibre step up to lead SMA Europe.  Nicole has a scientific background, working […]


  4. AveXis’ name is changed to Novartis Gene Therapies EU Ltd

    AveXis, which has been part of Novartis since 2018, is becoming Novartis Gene Therapies, EU Ltd. (Novartis Gene Therapies) a new unit dedicated to developing innovative AAV-based gene therapies. While the name of the organisation changes, the commitment to patients and their families remains steadfast. Novartis Gene Therapies will continue to focus on the research, […]